Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.9100 -0.0052 (-0.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups 
Via TheNewswire.com
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Via ACCESSWIRE
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groups 
Via TheNewswire.com
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
Via ACCESSWIRE
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Kelowna, British Columbia – October 16, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced... 
Via TheNewswire.com
Topics Regulatory Compliance
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
Via ACCESSWIRE
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
Via ACCESSWIRE
Lexaria Welcomes Industry Veteran as New CEO
Via ACCESSWIRE
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Update on Growth of GLP-1 Market Space, Notes Potential for Oral Delivery
Via Investor Brand Network
Topics Intellectual Property
Lexaria Updates Current GLP-1 Market
Via ACCESSWIRE
HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Strengthen Executive Team in Anticipation of ‘Strong Growth’ into 2025
Via Investor Brand Network
Topics Intellectual Property
Lexaria Appoints Michael Shankman as Chief Financial Officer
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide
Via CannabisNewsWire
Topics Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations
Via CannabisNewsWire
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Demonstrates Continued DehydraTECH(TM)-Liraglutide Performance with Ongoing GLP-1 Diabetes Animal Study
Via Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO
Via Investor Brand Network
Topics Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) Liraglutide in Ongoing Diabetes Animal Study
Via Investor Brand Network
Lexaria Releases Strategic Letter from the Outgoing CEO
Via ACCESSWIRE
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreement to Evaluate DehydraTECH(TM) Technology in Pre-Clinical Setting
Via Investor Brand Network
Topics Intellectual Property
Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.